Results 211 to 220 of about 81,528 (247)

Double‐Blind Placebo Challenge Confirmation of Diphenhydramine Allergy

open access: yesClinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Diphenhydramine, a first‐generation H1–antihistamine commonly used for allergic symptom relief and infusion premedication, rarely causes true systemic hypersensitivity. When suspected reactions are mild and subjective—particularly in anxious patients—objective confirmation is essential.
Ruchi Patel   +2 more
wiley   +1 more source

Integrative Genetic Perspectives: Decoding the Relationship Between Micronutrients, Inflammatory Cytokines, and Inflammatory Skin Diseases

open access: yesFood Science &Nutrition, Volume 14, Issue 4, April 2026.
This Mendelian randomization study investigated causal relationships between 15 micronutrients, 91 inflammatory proteins, and 13 inflammatory skin diseases. Genetically predicted higher Vitamin B6 levels showed a significant causal association with increased risk of hidradenitis suppurativa (FDR < 0.05).
Shengliang Gu   +4 more
wiley   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

open access: yesInternational Journal of Dermatology, Volume 65, Issue 4, Page 706-723, April 2026.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska   +8 more
wiley   +1 more source

Epidemiology and Genetics of Rheumatic Diseases Suggest a Constant Rate of DNA Damage as Underlying Cause

open access: yesImmunology, Volume 177, Issue 4, Page 736-748, April 2026.
A constant rate of DNA damage that is not perfectly repaired will cause a constant rate of DNA mutations. The chance of mutation will increase if DNA is prone to damage, such as occurs in somatic hypermutation (SHM) hotspots and GC‐rich DNA. Thus, if one mutation‐prone DNA site drives disease, the age of onset of disease and degree of penetrance should
Piet C. de Groen
wiley   +1 more source

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page 617-625, April 2026.
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba   +11 more
wiley   +1 more source

Does clinical exposure to different skin tones during training improve diagnostic ability?

open access: yesMedical Education, Volume 60, Issue 4, Page 410-417, April 2026.
Abstract Background Previous studies have shown that medical students demonstrate poorer performance when diagnosing pathology in skin of colour (SOC) compared to white skin (WS); it is important to understand the reasons underpinning this. If not addressed, poorer differential diagnostic ability in certain skin tones could entrench existing racial ...
Yusra Shammoon   +10 more
wiley   +1 more source

BRIDGE implementation science study to improve chronic spontaneous urticaria outcomes in Italy. [PDF]

open access: yesJ Allergy Clin Immunol Glob
Asero R   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy